These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22823204)

  • 21. Discovery and design of carbohydrate-based therapeutics.
    Cipolla L; Araújo AC; Bini D; Gabrielli L; Russo L; Shaikh N
    Expert Opin Drug Discov; 2010 Aug; 5(8):721-37. PubMed ID: 22827796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patented PDE10A inhibitors: novel compounds since 2007.
    Kehler J; Kilburn JP
    Expert Opin Ther Pat; 2009 Dec; 19(12):1715-25. PubMed ID: 19939189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How can high-throughput screening deliver drugs to treat atherosclerosis?
    Yang Y; Wang L; Si S; Hong B
    Expert Opin Drug Discov; 2010 Dec; 5(12):1175-88. PubMed ID: 22822720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practical metabolomics in drug discovery.
    Wilcoxen KM; Uehara T; Myint KT; Sato Y; Oda Y
    Expert Opin Drug Discov; 2010 Mar; 5(3):249-63. PubMed ID: 22823021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipophilicity in drug discovery.
    Waring MJ
    Expert Opin Drug Discov; 2010 Mar; 5(3):235-48. PubMed ID: 22823020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A structural feature-based computational approach for toxicology predictions.
    Valerio LG; Yang C; Arvidson KB; Kruhlak NL
    Expert Opin Drug Metab Toxicol; 2010 Apr; 6(4):505-18. PubMed ID: 20074001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems.
    Honma M; Kozawa M; Suzuki H
    Expert Opin Drug Discov; 2010 May; 5(5):491-511. PubMed ID: 22823132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacophore models for GABA(A) modulators: implications in CNS drug discovery.
    Ghoshal N; Vijayan RS
    Expert Opin Drug Discov; 2010 May; 5(5):441-60. PubMed ID: 22823129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in 2D fingerprint similarity searching.
    Geppert H; Bajorath J
    Expert Opin Drug Discov; 2010 Jun; 5(6):529-42. PubMed ID: 22823165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds.
    Prado-Prado FJ; González-Díaz H; de la Vega OM; Ubeira FM; Chou KC
    Bioorg Med Chem; 2008 Jun; 16(11):5871-80. PubMed ID: 18485714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved machine learning models for predicting selective compounds.
    Ning X; Walters M; Karypis G
    J Chem Inf Model; 2012 Jan; 52(1):38-50. PubMed ID: 22107358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in visual representation of molecular potentials.
    Du QS; Huang RB; Chou KC
    Expert Opin Drug Discov; 2010 Jun; 5(6):513-27. PubMed ID: 22823164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.
    Hausheer FH; Kochat H; Parker AR; Ding D; Yao S; Hamilton SE; Petluru PN; Leverett BD; Bain SH; Saxe JD
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S3-15. PubMed ID: 12819940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in LC platforms for drug discovery.
    Nicoli R; Martel S; Rudaz S; Wolfender JL; Veuthey JL; Carrupt PA; Guillarme D
    Expert Opin Drug Discov; 2010 May; 5(5):475-89. PubMed ID: 22823131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. When analoging is not enough: scaffold discovery in medicinal chemistry.
    Zhao H; Akritopoulou-Zanze I
    Expert Opin Drug Discov; 2010 Feb; 5(2):123-34. PubMed ID: 22822912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platforms for the identification of GPCR targets, and of orthosteric and allosteric modulators.
    Franco R; Canela EI; Casado V; Ferre S
    Expert Opin Drug Discov; 2010 Apr; 5(4):391-403. PubMed ID: 22823089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computational tools for polypharmacology and repurposing.
    Achenbach J; Tiikkainen P; Franke L; Proschak E
    Future Med Chem; 2011 Jun; 3(8):961-8. PubMed ID: 21707399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Charting, navigating, and populating natural product chemical space for drug discovery.
    Lachance H; Wetzel S; Kumar K; Waldmann H
    J Med Chem; 2012 Jul; 55(13):5989-6001. PubMed ID: 22537178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in targeted therapeutic agents.
    Nicolaides NC; Sass PM; Grasso L
    Expert Opin Drug Discov; 2010 Nov; 5(11):1123-40. PubMed ID: 22827748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.